Moh H. Malek

Prof. Moh H. Malek


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2011 in The Journal of Physiology
Verified
Journal Article
Closed access
LNLeonardo Nogueira
Leonardo Nogueira
IRIsrael Ramirez‐Sanchez
Israel Ramirez‐Sanchez
GPGuy A. Perkins
Guy A. Perkins
AMAnne Murphy
Anne Murphy
Pam TaubPam Taub
Pam Taub
Moh H. MalekMoh H. Malek
Moh H. Malek

19 December 2005 in BioMedical Engineering OnLine
Verified
Journal Article
Open access
TBTravis W Beck
Travis W Beck
THTerry J Housh
Terry J Housh
Joel T. CramerJoel T. Cramer
Joel T. Cramer
JWJoseph P Weir
Joseph P Weir
GJGlen O Johnson
Glen O Johnson
MMMichelle Mielke
Michelle Mielke
The purpose of this review is to examine the literature that has investigated mechanomyographic (MMG) amplitude and frequency responses during dynamic muscle actions. To date, the majority of MMG research has focused on isometric muscle actions. Recent studies, however, have examined the MMG time and/or frequency domain responses during various types of dynamic activities, including dynamic constant external resistance (DCER) and isokinetic muscle actions, as well as cycle ergometry. Despite the potential influences of factors such as changes in muscle length and the thickness of the tissue between the muscle and the MMG sensor, there is convincing evidence that during dynamic muscle actions, the MMG signal provides valid information regarding muscle function. This argument is supported by consistencies in the MMG literature, such as the close relationship between MMG amplitude and power output and a linear increase in MMG amplitude with concentric torque production. There are still many issues, however, that have yet to be resolved, and the literature base for MMG during both dynamic and isometric muscle actions is far from complete. Thus, it is important to investigate the unique applications of MMG amplitude and frequency responses with different experimental designs/methodologies to continually reassess the uses/limitations of MMG.

1 August 2006 in Chest
Verified
Journal Article
Closed access
Moh H. MalekMoh H. Malek
Moh H. Malek
DBDale E. Berger
Dale E. Berger
THTerry J. Housh
Terry J. Housh
WMWilliam D. Marelich
William D. Marelich
JCJared W. Coburn
Jared W. Coburn
TBTravis W. Beck
Travis W. Beck

1 October 2006 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
Moh H. MalekMoh H. Malek
Moh H. Malek
DBDale E. Berger
Dale E. Berger
WMWilliam D. Marelich
William D. Marelich
JCJared W. Coburn
Jared W. Coburn
TBTravis W. Beck
Travis W. Beck
THTerry J. Housh
Terry J. Housh
The purpose of this study was to use a meta-analytical technique to examine the efficacy of surgical repair of pectus excavatum on pulmonary function. Studies were retrieved via computerized literature searches, cross-referencing from original and review articles. Inclusion criteria were as follows: (1) reporting quantitative measures of preoperative and postoperative pulmonary function; (2) published in the English language; (3) indexed between January 1960 and September 2005; (4) reporting the duration between which preoperative and postoperative assessments were conducted; and (5) describing the pulmonary assessment procedures. The titles and abstracts of potentially relevant articles were reviewed to determine whether they met the criteria for inclusion. Twelve studies representing 313 pectus excavatum patients met the inclusion criteria and were used for the meta-analysis. Random-effects modeling yielded a mean weighted effect size (ES) for pulmonary function which was statistically nonsignificant (ES=0.08, 95% CI=-0.20 to 0.35; P=0.58). The findings of the present study indicated that surgical repair of pectus excavatum does not significantly improve pulmonary function. These findings, however, may be a result of testing pulmonary function under conditions in which pectus excavatum does not manifest itself.

12 March 2024 in Cells
Verified
Journal Article
Open access
PDF file
PMPaul Morse
Paul Morse
Tasnim ArroumTasnim Arroum
Tasnim Arroum
JWJunmei Wan
Junmei Wan
LPLucynda Pham
Lucynda Pham
AVAsmita Vaishnav
Asmita Vaishnav
Maik HüttemannMaik Hüttemann
Maik Hüttemann
Cytochrome c (Cytc) has both life-sustaining and cellular death-related functions, depending on subcellular localization. Within mitochondria, Cytc acts as a single electron carrier as part of the electron transport chain (ETC). When released into the cytosol after cellular insult, Cytc triggers the assembly of the apoptosome, committing the cell to intrinsic apoptosis. Due to these dual natures, Cytc requires strong regulation by the cell, including post-translational modifications, such as phosphorylation and acetylation. Six phosphorylation sites and three acetylation sites have been detected on Cytc in vivo. Phosphorylations at T28, S47, Y48, T49, T58, and Y97 tend to be present under basal conditions in a tissue-specific manner. In contrast, the acetylations at K8, K39, and K53 tend to be present in specific pathophysiological conditions. All of the phosphorylation sites and two of the three acetylation sites partially inhibit respiration, which we propose serves to maintain an optimal, intermediate mitochondrial membrane potential (ΔΨm) to minimize reactive oxygen species (ROS) production. Cytc phosphorylations are lost during ischemia, which drives ETC hyperactivity and ΔΨm hyperpolarization, resulting in exponential ROS production thus causing reperfusion injury following ischemia. One of the acetylation sites, K39, shows a unique behavior in that it is gained during ischemia, stimulating respiration while blocking apoptosis, demonstrating that skeletal muscle, which is particularly resilient to ischemia-reperfusion injury compared to other organs, possesses a different metabolic strategy to handle ischemic stress. The regulation of Cytc by these post-translational modifications underscores the importance of Cytc for the ETC, ΔΨm, ROS production, apoptosis, and the cell as a whole.

10 November 2024 in Redox Biology
Verified
Journal Article
Open access
LPLucynda Pham
Lucynda Pham
Tasnim ArroumTasnim Arroum
Tasnim Arroum
JWJunmei Wan
Junmei Wan
LPLauren Pavelich
Lauren Pavelich
JBJamie Bell
Jamie Bell
Maik HüttemannMaik Hüttemann
Maik Hüttemann
Mitochondria are essential to cellular function as they generate the majority of cellular ATP, mediated through oxidative phosphorylation, which couples proton pumping of the electron transport chain (ETC) to ATP production. The ETC generates an electrochemical gradient, known as the proton motive force, consisting of the mitochondrial membrane potential (ΔΨm, the major component in mammals) and ΔpH across the inner mitochondrial membrane. Both ATP production and reactive oxygen species (ROS) are linked to ΔΨm, and it has been shown that an imbalance in ΔΨm beyond the physiological optimal intermediate range results in excessive ROS production. The reaction of cytochrome c oxidase (COX) of the ETC with its small electron donor cytochrome c (Cytc) is the proposed rate-limiting step in mammals under physiological conditions. The rate at which this redox reaction occurs controls ΔΨm and thus ATP and ROS production. Multiple mechanisms are in place that regulate this reaction to meet the cell's energy demand and respond to acute stress. COX and Cytc have been shown to be regulated by all three main mechanisms, which we discuss in detail: allosteric regulation, tissue-specific isoforms, and post-translational modifications for which we provide a comprehensive catalog and discussion of their functional role with 55 and 50 identified phosphorylation and acetylation sites on COX, respectively. Disruption of these regulatory mechanisms has been found in several common human diseases, including stroke and myocardial infarction, inflammation including sepsis, and diabetes, where changes in COX or Cytc phosphorylation lead to mitochondrial dysfunction contributing to disease pathophysiology. Identification and subsequent targeting of the underlying signaling pathways holds clear promise for future interventions to improve human health. An example intervention is the recently discovered noninvasive COX-inhibitory infrared light therapy that holds promise to transform the current standard of clinical care in disease conditions where COX regulation has gone awry.